SHORLA
PharmaSHORLA is a pharmaceutical company focused on Oncology, Immunology. Key products include JYLAMVO.
SHORLA's Key Drugs
SHORLA's core commercial portfolio centers on JYLAMVO, TEPYLUTE, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
SHORLA's Recent FDA Approvals
New NDA/BLA approvals for SHORLA over the last two years — novel drugs only, excluding generics and label supplements.
SHORLA's Therapeutic Areas
SHORLA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SHORLA's Top Competitors
SHORLA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SHORLA Pipeline Snapshot
Active clinical trials for SHORLA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • JYLAMVO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling